Venquis Therapeutics discovers and develops mechanistically differentiated targeted small molecule direct protein degraders. Our proprietary CIPD platform enables drug discovery of this highly novel targeting approach, enabling direct non-covalent binding and subsequent destruction of virtually any protein target in a mutant-selective fashion: degrading the driver-mutant proteins while sparing their endogenous counterparts. This is a powerful approach for cancer, inflammatory, and degenerative targets. Our two lead programs are for traditionally difficult to drug targets, for which our initial novel (patentable) small molecules have shown excellent results – with the potential for best-in-class and first-in-class respectively.